Cyclerion receives FDA feedback on depression treatment study Feb 17, 2026 07:00AM
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board Feb 17, 2026 07:00AM
Cyclerion partners with Medsteer for depression treatment development Jan 5, 2026 04:01PM
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression Jan 5, 2026 04:01PM
Cyclerion Therapeutics (CYCN) Regains Nasdaq Compliance Jun 1, 2023 04:00PM
View Older Stories

Jun 1, 2023 04:00PM Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 15, 2023 01:00PM Cyclerion Therapeutics (CYCN) announces 1-for-20 reverse stock split
May 15, 2023 01:00PM Cyclerion Announces Reverse Stock Split
May 12, 2023 05:36AM Cyclerion Therapeutics (CYCN) to Sell Zagociguat and CY3018
May 11, 2023 06:00PM Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
May 11, 2023 06:00PM Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
Apr 3, 2023 07:30AM Cyclerion Therapeutics (CYCN) Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
Apr 3, 2023 07:30AM Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
Apr 3, 2023 07:30AM Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
Mar 27, 2023 07:02AM Cyclerion Therapeutics (CYCN) Granted FDA Orphan Drug Designation for Zagociguat
Mar 27, 2023 07:00AM Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
Mar 27, 2023 07:00AM Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
Mar 22, 2023 04:40PM Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
Mar 22, 2023 04:40PM Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
Nov 22, 2022 07:04AM Cyclerion Therapeutics (CYCN) Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
Nov 22, 2022 07:00AM Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
Nov 22, 2022 07:00AM Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
Oct 6, 2022 08:03AM Cyclerion Therapeutics (CYCN) Announces Mitochondrial Disease-Focused Corporate Strategy
Oct 6, 2022 08:00AM Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
Oct 6, 2022 08:00AM Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
Aug 9, 2022 04:00PM Cyclerion Therapeutics (CYCN) Announces CY6463 Pipeline Progress; Reports Q2
Aug 9, 2022 04:00PM Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
Aug 9, 2022 04:00PM Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
Jul 28, 2022 07:12AM Cyclerion Therapeutics (CYCN) Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia
Jul 28, 2022 07:02AM Cyclerion Therapeutics (CYCN) Reports Positive Topline Clinical Data for CY6463
Jul 28, 2022 07:00AM Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
Jul 28, 2022 07:00AM Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
Jul 26, 2022 07:02AM Cyclerion Therapeutics (CYCN) Appoints Steven E. Hyman to its Board
Jul 26, 2022 07:00AM Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
Jul 26, 2022 07:00AM Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
Jun 28, 2022 09:04AM Cyclerion Therapeutics (CYCN) Provides Additional Positive CY6463 MELAS Data
Jun 28, 2022 09:00AM Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Jun 28, 2022 09:00AM Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Jun 22, 2022 08:30AM Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Jun 22, 2022 08:30AM Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Jun 17, 2022 08:02AM Cyclerion Therapeutics (CYCN) Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
Jun 17, 2022 08:00AM Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
Jun 17, 2022 08:00AM Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
Jun 10, 2022 07:00AM Cyclerion Therapeutics (CYCN) Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
Jun 10, 2022 07:00AM Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
Jun 10, 2022 07:00AM Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
Jun 6, 2022 07:00AM Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
Jun 6, 2022 07:00AM Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
May 4, 2022 04:05PM Cyclerion Therapeutics (CYCN) Reports on CY6463 Clinical Pipeline Progress
May 4, 2022 04:01PM Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
May 4, 2022 04:01PM Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
Feb 24, 2022 04:01PM Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
Feb 24, 2022 04:01PM Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
Feb 23, 2022 08:00AM Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
Feb 23, 2022 08:00AM Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
View Older Stories